


Form PTO-1449
(REV. 8-03)

U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket
2003946-0056
(ANDI/CIP)

In re Application No.
Not Yet Assigned
10/657,910



INFORMATION
DISCLOSURE STATEMENT
(Use several sheets if necessary)

Applicant: Chiba *et al*

Filing Date:
September 9, 2003

Group:
NYA-1625

U.S. PATENT DOCUMENTS

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
BT	† 5,674,892	Giese, et al.	October 7, 1997	514	450
BT	† 5,727,726	Giese, et al	March 17, 1998	514	449
BT	† 5,795,910	Giese, et al.	August 18, 1998	514	450
BT	† 6,265,603 B1	Lewis, et al.	July 24, 2001	560	9

U.S. PATENT APPLICATIONS

Examiner's Initials:	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document No.	Country	International Publication Date	Translation	
				Yes	No
BT	EP 0 606 044 A1	EP	November 29, 1993		
BT	GB 2 323 845 A	UK	October 7, 1998		
BT	JP 8- 40893	JP	February 13, 1996		X
BT	WO 96/13259	PCT	May 9, 1996		
BT	WO 00/38674	PCT	July 6, 2000		
BT	WO 00/39314	PCT	July 6, 2000		
BT	WO 01/36003 A2	PCT	May 25, 2001		
BT	WO 02/48136 A1	PCT	June 20, 2002		X

OTHER DOCUMENTS

Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)
BT	Copy of International Search Report for PCT/US03/07377.
BT	Agatsuma, et al., "Revised Structure and Stereochemistry of Hypothemycin", <i>Chem.Pharm.Bull.</i> ; 41(2): 373-375 1993.
BT	Chen, et al., "Activation of p38 MAP kinase and ERK are required for ultraviolet-B induced c-fos gene expression in human keratinocytes", <i>Oncogene</i> , 18: 7649-7476, 1999.
BT	Dombrowski, et al., "Production of a Family of Kinase-inhibiting Lactones from Fungal Fermentations", <i>J. Antibiot.</i> , 52(12): 1077-1085, 1999.

† Copies of references not included – requirement waived pursuant to USPTO OG Notice of 8/5/03

U.S.S.N. 10/657,910
3721649_1.DOC

1 of 2

Attorney Docket No. 2003946-0056
Client Reference No.: ANDI/CIP

Form PTO-1449
(REV. 8-03)

U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket
2003946-0056
(ANDI/CIP)

In re Application No.
~~Not Yet Assigned~~

10/657,910

INFORMATION

DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant: Chiba *et al*

Filing Date:
September 9, 2003

Group:
NYA 1625

BT Ellestad, et al., "New Zearalenone Related Macrolides and Isocoumarins from an Unidentified Fungus", *J. Org. Chem.*, 43(12):2339-2343, 1978.

BT Li, et al., "Rays and arrays: the transcriptional program in the response of human epidermal keratinocytes to UVB illumination", *The FASEB Journal*, Article 10.1096/fj.01-0172fje, published online September 17, 2001.

BT Kastelic, et al., "Induction of Rapid IL-1 β mRNA Degradation in THP-1 Cells Mediated Through the AU-Rich Region in the 3'UTR by a Radicicol Analogue", *Cytokine* 8(10): 751-761, 1996.

BT Matsuoka, et al., "Inhibition of HgCl₂-induced mitogen-activated protein kinase activation by LL-Z1640-2 in CCRF-CEM cells", *Eur. J. Pharmacol.*, 409(2): 155-158, 2000.

BT Rawlins, et al., "Inhibition of endotoxin-induced TNF- α production in macrophages by 5Z-7-oxozeaenol and other fungal resorcylic acid lactones", *Int. J. Immunopharmacol.*, 21(12): 799-814, 1999.

BT Tak, et al., "NF- κ B-a key role in inflammatory diseases", *J. Clin. Investigation*, 107(1): 7-11, 2001.

BT Takehana, et al., "A radicicol-Related Macrocyclic Nonaketide Compound, Antibiotic LL-Z1640-2, Inhibits the JNK/p38 Pathways in Signal-Specific Manner", *Biochem. Biophys. Res. Commun.*, 257(1): 19-23, 1999.

BT Tatsuta, et al., "The First Total Synthesis of a Macrocyclic Anti-protozoan, LL-Z1640-2", *Chem. Lett.*, Vol. 2, 172-173, 2001.

BT Yamamoto, et al., "Therapeutic potential of inhibition of the NF- κ B pathway in the treatment of inflammation and cancer", *J. Clin. Investigation*, 107(2), 135-142, 2001.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Copies of references not included – requirement waived pursuant to USPTO OG Notice of 8/5/03

U.S.S.N. 10/657,910
3721649_1.DOC

2 of 2

Attorney Docket No. 2003946-0056
Client Reference No.: ANDI/CIP